Blog Category:

The Impact of Vaccine Hesitancy and Under-Vaccination in Pediatric Patients

Vaccine hesitancy in parents can lead to under-vaccination or the complete lack of vaccination in children and adolescents. This has been linked to outbreaks of vaccine-preventable diseases. Pediatric and school nurses are often the main source of information for parents …

NMOSD Unveiled: Optimizing Long-Term Outcomes in Neuromyelitis Optica Spectrum Disorder with Innovative Therapies

Neuromyelitis optica spectrum disorder (NMOSD) is a relatively new term for a group of rare, demyelinating autoimmune diseases affecting the central nervous system (CNS), particularly the optic nerves and spinal cord. In the past, NMOSD was conflated with multiple sclerosis …

Forging a New Frontier: Revolutionizing Iron Deficiency Therapy in Patients with Inflammatory Bowel Disease

Anemia occurs frequently in patients with inflammatory bowel disease (IBD) and is one of the most commonly seen extraintestinal manifestations of disease with iron deficiency (ID) as the most common cause. Practice guidelines recommend screening all patients with IBD regularly …

Recent and Emerging Therapeutic Options for Alzheimer’s Disease

In the treatment of Alzheimer’s disease (AD), health care professionals are in dire need of clinical confidence in the evidence-based potential of novel disease-modifying therapeutic options. Several promising classes of emerging agents such as amyloid-targeting humanized monoclonal antibodies (mAbs), incretin-based …

Current and Emerging Best Practices for the Timely Screening and Diagnosis of MCI Due to Alzheimer’s Disease

Dementia is most commonly caused by Alzheimer’s disease (AD), a multifactorial progression of neurodegeneration in which the accumulation of amyloid-beta and tau proteins in the brain and chronic and dysregulated inflammatory processes lead to significant cognitive impairment. Though novel diagnostic …

Visualizing the Future: Advances in IL-23-Targeted Therapies in the Treatment of IBD.

Interleukin (IL)-23 has been identified as a main driver of inflammation in the pathology of inflammatory bowel disease (IBD). While all agents in this anti-IL-23 class neutralize IL-23 by binding of the Fab fragment, differences in Fc fragment may be …

Life Disrupted: Role of Advanced Practice Providers in Guiding Patients with Crohn’s Disease Through the Challenges of Bowel Urgency

Up to 80% of patients with Crohn’s disease (CD) report some degree of bowel urgency, a symptom that not only significantly adds to their overall emotional and social burden but can be an indicator of uncontrolled bowel inflammation. Unfortunately, bowel …

What’s IL-23 Got to Do With It? Targeted Therapies in the Management of IBD

Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …

Adverse Events in the New Age of Front-line Combination Approaches in Advanced Gynecologic Cancers

Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers.  As these new combinations seek to further improve and enhance the efficacy of …